Prescription CBD oil could soon be available in Idaho (kivitv.com)
Topics: public policy, decision making, Idaho, drug policy, BOISE, case study, cannabidiol, legislative panel
“When we look at making public policy, we felt like we have to make sure it’s science and not politics that creates medical approval,” Fitzgerald said.
The FDA has until June 27 to make a decision on the approval of the drug.
“That information is supplemental, given to the [FDA advisory] panel to take a look at for safety and tolerability of the drug,” Idaho Office of Drug Policy Administrator Nicole Fitzgerald said.
Will Sessions Respond to Gupta on ‘Weed vs. Opioids’ at Friday Meeting? (mgretailer.com)
Topics: law enforcement, medical cannabis, Cnn, media reports, opioid, overdose deaths, gateway drug, Montana
In “Weed 4: Weed vs. opioids,” Gupta will look at the potential for medical cannabis to be used in treatment for those suffering from the national opioid crisis.
Prior to the debut, Gupta has penned an open letter to U.S. attorney general Jeff Sessions, stating that medical cannabis has benefits for a wide spectrum of health conditions, but also has significant potential as an alternative treatment for those suffering from opioid addiction.
CBD oil for epilepsy treatment backed up by more studies (herb.co)
Topics: clinical studies, medical professionals, scientific evidence, recent studies, seizure reduction, second study, cannabidiol, severe cases
That is to say nothing of the legal risks many people have to take in order to acquire CBD oil that, in many cases, is more effective than those prescribed by their doctor’s.
Many people who suffer from severe cases of epilepsy, such as Dravet syndrome have responded well to CBD oil, both anecdotally and in a number of recent studies.
Jack is amongst a growing number of people, both adults and children who have found a measure of relief from the seizures by using .
An unlikely advocate for medical marijuana legalization | The GroundTruth Project (thegroundtruthproject.org)
Topics: Korea, South Korea, advocacy group, medical cannabis, advocacy work, medical marijuana, America, SEOUL
The doctor is one of small group advocating for legalizing medical marijuana, and she has found an unlikely ally in a man of God.
But now that more states in the U.S. are decriminalizing medical marijuana—she thinks that attitudes will change in South Korea, resulting in decriminalization in South Korea in the near future.
He pulls up an official statement from the Methodist Church on his smartphone that states that the Church believes that “seriously ill people should not be subject to criminal sanctions for using marijuana if the patient’s physician has told the patient that such use is likely to be beneficial.” He feels emboldened, knowing that his advocacy work is supported by the Methodist Church.
If the general public sees marijuana as immoral, is a Methodist minister one of the few people South Koreans will listen to when he says the substance isn’t bad?
Cannabidiol Oil (CBD Oil) Market By Manufacturers, Countries, Type And Application, Forecast To 2023 – Financial Analyst (theanalystfinancial.com)
Topics: reliable sources, annual reports, market conditions, market potential, SWOT, product price, market experts, industrial experts
Cannabidiol Oil (CBD Oil) Market report is to help the user understand the market in terms of its classification, segmentation, market potential, influential trends, and the challenges that the industry is facing.
Deep researches and analysis were done during the preparation of the Cannabidiol Oil (CBD Oil) Market report.The report contains the SWOT analysis of the market.
Mother makes homemade medical marijuana oil for disabled son (newjersey.news12.com)
Topics: medical marijuana, state law, Food and Drug Administration, New Jersey, Middlesex County, side effects, health conditions, potential side effects
But the family says that after he began taking the THC oil, he was able to play with his siblings and family dog.
But his mother Jean Lucas says that the drug has only been stopping his seizures for one year.
How FDA Approved Cannabis Products Could Affect CBD Distribution Channels (newcannabisventures.com)
Topics: drug development, medical cannabis, GlaxoSmithKline, dietary supplement, health claims, patient outcomes, human services, marketing practices
Brightfield Group, a market research firm based in Chicago, expects CBD products to grow from 5% of U.S. cannabis sales today to 12% by 2021, and this doesn’t include the pharmaceutical channel that would open up with the approval of Epidiolex.
The bottom-line, then, is that approval of Epidiolex is likely to be a boon for patients suffering from epilepsy and to open the door to a pharmaceutical distribution pathway for cannabis-derived drugs, but it is also likely to drive significant interest in the broader CBD category.
While there have been some concerns in the industry that GW Pharma might take action to block the sale of CBD by other providers upon approval of Epidiolex by the FDA, we believe this is not the case based on many discussions we have had with the company over the years.
While cannabis or even CBD aren’t required to be rescheduled in order for it to be approved and then marketed by GW Pharma, the approval by the FDA of a CBD product derived from cannabis plants could play a role in the scheduling status of CBD or cannabis in the future.
We believe that the landmark approval of a cannabis-derived drug will not only spur further research and development of FDA-approved cannabis products but also accelerate an already rapidly growing market for the health and wellness market for CBD products, which are derived from industrial hemp and cannabis plants and sold in dispensaries, mail-order or other channels.